These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 2563302

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.
    Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN.
    Cancer Res; 1990 Mar 15; 50(6):1748-56. PubMed ID: 1968358
    [Abstract] [Full Text] [Related]

  • 3. Structure-activity relationships of phenothiazines and related drugs for inhibition of protein kinase C.
    Aftab DT, Ballas LM, Loomis CR, Hait WN.
    Mol Pharmacol; 1991 Nov 15; 40(5):798-805. PubMed ID: 1944244
    [Abstract] [Full Text] [Related]

  • 4. The primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm.
    Wuonola MA, Palfreyman MG, Motohashi N, Kawase M, Gabay S, Gupta RR, Molnár J.
    Anticancer Res; 1998 Nov 15; 18(1A):337-48. PubMed ID: 9568100
    [Abstract] [Full Text] [Related]

  • 5. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM, Liang YJ, Ruan JW, Ding Y, Wang XW, Shi Z, Gu LQ, Yang XP, Fu LW.
    J Pharm Pharmacol; 2004 Aug 15; 56(8):1061-6. PubMed ID: 15285852
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells.
    Molnár J, Hevér A, Fakla I, Fischer J, Ocsovski I, Aszalós A.
    Anticancer Res; 1997 Aug 15; 17(1A):481-6. PubMed ID: 9066699
    [Abstract] [Full Text] [Related]

  • 7. Characterization of 2-chloro-N10-substituted phenoxazines for reversing multidrug resistance in cancer cells.
    Thimmaiah KN, Jayashree BS, Germain GS, Houghton PJ, Horton JK.
    Oncol Res; 1998 Aug 15; 10(1):29-41. PubMed ID: 9613455
    [Abstract] [Full Text] [Related]

  • 8. Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring.
    Lee Y, Yeo H, Liu SH, Jiang Z, Savizky RM, Austin DJ, Cheng YC.
    J Med Chem; 2004 Oct 21; 47(22):5555-66. PubMed ID: 15481991
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.
    Hait WN, Pierson NR.
    Cancer Res; 1990 Feb 15; 50(4):1165-9. PubMed ID: 2297765
    [Abstract] [Full Text] [Related]

  • 13. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists.
    Yang JM, Goldenberg S, Gottesman MM, Hait WN.
    Cancer Res; 1994 Feb 01; 54(3):730-7. PubMed ID: 7905786
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
    Jin J, Wang FP, Wei H, Liu G.
    Cancer Chemother Pharmacol; 2005 Feb 01; 55(2):179-88. PubMed ID: 15378274
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.